IgA Nephropathy Clinical Trial
Official title:
A Single-arm, Forward-looking, Exploratory Clinical Study of Telitacicept in Patients With Refractory IgA Nephropathy
Verified date | October 2022 |
Source | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy. The main questions it aims to answer are: - To evaluate the clinical efficacy of Telitacicept in patients with refractory IgA nephropathy. - To evaluate the safety and adverse reaction of Telitacicept in patients with refractory IgA nephropathy. Participants will be subcutaneously injected with 240mg of Telitacicept once per week. Study subject: After 6 months of sequential treatment with renin-angiotensin system (RAS) blockers or glucocorticoids, patients with pathological biopsy of 0.7≥5 g/24 hours of proteinuria was confirmed as refractory IgA nephropathy.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | September 30, 2026 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Voluntarily sign the informed consent form. 2. IgA nephropathy was confirmed by pathological biopsy. 3. Age range: = 18 years old, = 70 years old, male or female. 4. During the screening period, the 24-hour urine protein of Visit 1 and Visit 2 should meet at least one =0.75g/24h, and the 24-hour urine protein = 0.75g/24h at Visit 3. 5. Measured glomerular filtration rate or estimated GFR (using the CKD-EPI formula) > 35 mL/min/1.73 m2. 6. Participants had received a basic regimen including ACE inhibitors/ARBs for 12 weeks prior to randomization, and the dose of ACE inhibitors/ARBs (within the maximum tolerated range) was stable for 4 weeks prior to randomization. Exclusion Criteria: 1. Abnormal laboratory indicators of participants need to be excluded. 2. Secondary IgA nephropathy need to be excluded. 3. Specific pathologic or clinical renal disease types, and IgA nephropathy that may require hormone therapy. 4. Patients who have experienced any of the following cardiovascular and cerebrovascular events within the 12 weeks prior to screening. 5. Use of systemic corticosteroids within 3 months prior to randomization (except local, nasal inhalation, etc.) 6. Immunosuppressants were used within 3 months prior to randomization. 7. Patients requiring hospitalization for active infection or intravenous anti-infective therapy within 3 months prior to randomization. 8. Previously or currently diagnosed active tuberculosis Untreated latent tuberculosis. 9. Herpes zoster HIV antibody positive or HCV antibody positive during the screening period. 10. Those who currently have active hepatitis or have severe liver disease and medical history. 11. Patients with malignant tumors. 12. Pregnant and lactating women, and men or women with planned children during the trial period. 13. Those who could not avoid the use of nephrotoxic drugs during the trial. 14. Allergic to human biological products. 15. Patients who have been given any of the clinical trial drugs 4 weeks prior to randomization or within 5 times the half-life of the experimental drug (whichever is longer). 16. Patients deemed ineligible for the trial by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete clinical response | a. Proteinuria: protein-to-creatinine ratio <0.2; b. Stable renal function: eGFR decreased by less than 5ml/min/1.73m2 from baseline at the end of the 3-year trial phase. | 3-year | |
Primary | The absolute value of eGFR | The absolute value of eGFR decreased by more than 15 ml/min/1.73m2 over 3 years from baseline | 3-year | |
Primary | Changes in 24-hour urinary protein | Changes in 24-hour urinary protein at week 104 compared with baseline. | 104 weeks | |
Secondary | eGFR decrease | The estimated glomerular filtration rate (eGFR) decreased by more than 30 ml/min/1.73 m2 from baseline. | 3-year | |
Secondary | Need for dialysis | progression to end-stage renal disease | 3-year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016323 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
|
Phase 2 | |
Withdrawn |
NCT02433236 -
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT02231125 -
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
|
Phase 4 | |
Completed |
NCT01502579 -
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
|
N/A | |
Not yet recruiting |
NCT01203007 -
Diet Intervention in Food Sensitive Patients With IgA Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00657059 -
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
|
Phase 3 | |
Recruiting |
NCT04684745 -
Open-Label Extension Study of BION-1301 in IgA Nephropathy
|
Phase 2 | |
Completed |
NCT03719443 -
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02112838 -
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
|
Phase 2 | |
Withdrawn |
NCT02052219 -
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
|
Phase 3 | |
Completed |
NCT00767221 -
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
|
Phase 2 | |
Recruiting |
NCT04438603 -
The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Terminated |
NCT04905212 -
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
|
Phase 2 | |
Terminated |
NCT04042623 -
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT03633864 -
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
|
Phase 2 | |
Not yet recruiting |
NCT06454110 -
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
|
Phase 2 | |
Recruiting |
NCT02954419 -
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
|
||
Recruiting |
NCT03001947 -
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
|